Key Drivers
- Cash Cushion
- Ongoing Losses
- Share Dilution
AIAI Summary
STTK's near-term survival risk has eased after the June financing, so the stock now hinges on whether SL-325 can deliver enough clinical proof to justify a diluted share count and a valuation that already prices in success, making upcoming Phase 2 data the decisive catalyst and main downside risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Cushion
- •Ongoing Losses
- •Share Dilution
STTK has a strong cash-rich balance sheet and very low leverage, but ongoing losses, negative cash flow, minimal revenue, and heavy dilution make it a survival story more than an operating one.
Price Behavior
Key Price Behavior Insights:
- •Support holding
- •Resistance capped
- •Rebound resilience
STTK is constructive but still range-bound, holding $7.14–$7.16 support after a sharp rebound while remaining capped below $7.49–$7.53 unless it breaks $7.53.
Sharp rebound from late-July weakness, but rallies are still being sold into
Sentiment & News
Key News Insights:
- •Bullish analyst view
- •SL-325 progress
- •Strong upside target
Shattuck Labs is drawing bullish analyst attention as strong price targets and SL-325's progress toward Phase 2 keep momentum and upside expectations elevated.
The latest headlines are likely supportive for STTK by reinforcing confidence in its pipeline and valuation upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings